Atossa Genetics Sponsors 8th Annual Walk with Love Fundraiser on May 17, 2015, Benefiting Dr. Susan Love Research Foundation's Innovative Breast Cancer Research

SEATTLE, WA--(Marketwired - May 14, 2015) - Atossa Genetics Inc. (NASDAQ: ATOS) announced today that it has partnered with Dr. Susan Love Research Foundation as a platinum sponsor for the 8^th Annual Walk with Love fundraiser benefiting Dr. Susan Love Research Foundation's innovative breast cancer research. Walk with Love is a 5K walk/run taking place on May 17, 2015, at the Palisades Recreation Center in Pacific Palisades, California, and virtually nationwide to support research into the cause and prevention of breast cancer.

Steven C. Quay, M.D., Ph.D., President and CEO of Atossa Genetics Inc., commented, "We are thrilled to support Dr. Susan Love Research Foundation and their innovative breast cancer research focused on finding the cause of breast cancer and ending it. We share a united vision and determination in our efforts to realize a future without breast cancer and we fully support the strident efforts of Dr. Susan Love Research Foundation in their mission."

"Breast cancer diagnoses are on the rise," said Dr. Susan Love, Chief Visionary Officer, Dr. Susan Love Research Foundation. "Our study of the collateral damage from today's breast cancer treatments reinforces the urgency of finding the cause so we can stop it before it starts. It is going to take everyone's participation -- as sponsors, walkers, supporters, and volunteers for research studies -- to end breast cancer. We welcome Atossa's commitment to our mission and collaboration to end this disease."

About Walk with Love

Walk with Love is a 5K walk/run fundraiser benefiting Dr. Susan Love Research Foundation's innovative breast cancer research. We hope you join us on May 17, 2015, at the Pacific Palisades Recreation Center in Pacific Palisades, California, and virtually nationwide to walk for a future without breast cancer.

• Register today to walk with us in Pacific Palisades or in your own community.
  
  
• Are you a returning walker/runner? Be sure to sign in on the registration page to make the process simpler.
  
  
• Learn more about Dr. Susan Love Research Foundation and our groundbreaking breast cancer research programs.
  
  

For more information about the Walk with Love Event please contact Events@DrSusanLoveResearch.org or call 1-866-569-0388.

About the Dr. Susan Love Research Foundation

Every day, 813 women are diagnosed with breast cancer. Dr. Susan Love Research Foundation is committed to finding the cause of breast cancer, which the Foundation believes will be the ultimate cure. The Foundation invests 83¢ of every dollar donated in research and programs, such as the Army of Women® and the Health of Women [HOW] Study™. It has the seal of approval from the BBB Giving Alliance, Charity Navigator, and Guidestar.

About Atossa Genetics

Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by its subsidiary, The National Reference Laboratory for Breast Health Inc. The laboratory services and the Company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For more information, please visit www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, the outcome or timing of regulatory approvals needed by Atossa to sell its products, responses to regulatory matters, Atossa's ability to achieve its objectives, continue to manufacture and sell its products, recalls of products, the safety and efficacy of Atossa's products and services, performance of distributors, whether Atossa can launch and commercialize in the United States and foreign markets the additional tests, devices and therapeutics in its pipeline in a timely and cost effective manner, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time. Atossa does not undertake any obligation to update any forward-looking statement.